2023
Parental perspective on the risk of infertility and fertility preservation options for children and adolescents with sickle cell disease considering hematopoietic stem cell transplantation
Sinha C, Meacham L, Bakshi N, Ross D, Krishnamurti L. Parental perspective on the risk of infertility and fertility preservation options for children and adolescents with sickle cell disease considering hematopoietic stem cell transplantation. Pediatric Blood & Cancer 2023, 70: e30276. PMID: 37051746, PMCID: PMC10544372, DOI: 10.1002/pbc.30276.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationRisk of infertilitySickle cell diseaseStem cell transplantationFertility preservationCell transplantationCell diseaseMajor long-term complicationPrimary caregiversIdentical related donorsDisease-free survivalFertility preservation optionsFertility preservation proceduresLong-term complicationsHuman leukocyte antigenConditioning regimenHost diseaseRelated donorsLeukocyte antigenPreservation optionsHCT physiciansSurvival rateAvailable HLAEleven participantsInfertility
2022
Associated comorbidities, healthcare utilization & mortality in hospitalized patients with haemophilia in the United States: Contemporary nationally representative estimates
Day J, Takemoto C, Sharathkumar A, Makhani S, Gupta A, Bitner S, Josephson C, Bloch E, Tobian A, Krishnamurti L, Goel R. Associated comorbidities, healthcare utilization & mortality in hospitalized patients with haemophilia in the United States: Contemporary nationally representative estimates. Haemophilia 2022, 28: 532-541. PMID: 35412659, PMCID: PMC9540439, DOI: 10.1111/hae.14557.Peer-Reviewed Original ResearchConceptsNationwide Inpatient SampleHealthcare utilizationPrevalence of comorbiditiesAge-related comorbiditiesCentral line infectionsInpatient discharge databaseOverall mortality rateCatheter-related infectionsHealthcare utilization patternsMedian hospital chargesICD-10 codesRepresentative estimatesCause admissionsCause hospitalizationAdult PWHAssociated comorbidityCommon comorbiditiesHospitalized patientsMedian ageContemporary cohortHospital burdenHospital chargesDischarge databaseInpatient SampleLine infections
2020
Primary caregiver decision‐making in hematopoietic cell transplantation and gene therapy for sickle cell disease
Sinha C, Bakshi N, Ross D, Loewenstein G, Krishnamurti L. Primary caregiver decision‐making in hematopoietic cell transplantation and gene therapy for sickle cell disease. Pediatric Blood & Cancer 2020, 68: e28749-e28749. PMID: 33034129, PMCID: PMC8246626, DOI: 10.1002/pbc.28749.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationSickle cell diseasePrimary caregiversSCD complicationsCell transplantationCell diseaseDiminished qualityAutologous hematopoietic progenitor cellsPrimary caregiver reportMajor medical decisionsGene therapyCurative optionSevere complicationsHematopoietic progenitor cellsClinical trialsAcceptable treatmentRecent complicationsComplicationsCaregiver reportsCaregiversProgenitor cellsNormal lifeTransplantationTherapyMedical decisionsSafety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi‐center HGB‐206 trial
Tisdale J, Pierciey F, Bonner M, Thompson A, Krishnamurti L, Mapara M, Kwiatkowski J, Shestopalov I, Ribeil J, Huang W, Asmal M, Kanter J, Walters M. Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi‐center HGB‐206 trial. American Journal Of Hematology 2020, 95: e239-e242. PMID: 32401372, DOI: 10.1002/ajh.25867.Peer-Reviewed Original ResearchAssessment of Patient and Caregiver Attitudes and Approaches to Decision-Making Regarding Bone Marrow Transplant for Sickle Cell Disease
Bakshi N, Katoch D, Sinha C, Ross D, Quarmyne M, Loewenstein G, Krishnamurti L. Assessment of Patient and Caregiver Attitudes and Approaches to Decision-Making Regarding Bone Marrow Transplant for Sickle Cell Disease. JAMA Network Open 2020, 3: e206742. PMID: 32469414, PMCID: PMC7260617, DOI: 10.1001/jamanetworkopen.2020.6742.Peer-Reviewed Original ResearchConceptsBone marrow transplantCaregivers of patientsSickle cell diseasePatient decision aidMarrow transplantMedian ageCurative treatmentCell diseaseGroup 2Group 1Caregiver attitudesNovel disease-modifying therapiesDisease-modifying therapiesSickle cell clinicAssessment of patientsFuture prospective studiesRandomized clinical trialsParent trialProspective studyTreatment optionsClinical trialsNeeds assessment phaseMAIN OUTCOMECell clinicPatients
2019
Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial
Krishnamurti L, Ross D, Sinha C, Leong T, Bakshi N, Mittal N, Veludhandi D, Pham A, Taneja A, Gupta K, Nwanze J, Matthews A, Joshi S, Olivieri V, Arjunan S, Okonkwo I, Lukombo I, Lane P, Bakshi N, Loewenstein G. Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial. Journal Of Medical Internet Research 2019, 21: e14462. PMID: 31799940, PMCID: PMC6934048, DOI: 10.2196/14462.Peer-Reviewed Original ResearchConceptsRandomized clinical trialsPatient decision aidSickle cell diseaseWeb-based patient decision aidClinical trialsHealth care providersCell diseaseDecisional conflictPatient knowledgeCare providersDecision aid armStandard care armOttawa Decision Support FrameworkChronic blood transfusionsDisease-modifying therapiesBone marrow transplantationDecision aidCare armDecision aid prototypeClinical characteristicsBlood transfusionControlled TrialsPediatric patientsMarrow transplantationTherapeutic options
2018
Platelet transfusion practices in immune thrombocytopenia related hospitalizations
Goel R, Chopra S, Tobian A, Ness P, Frank S, Cushing M, Vasovic L, Kaicker S, Takemoto C, Josephson C, Nellis M, Bussel J, Krishnamurti L. Platelet transfusion practices in immune thrombocytopenia related hospitalizations. Transfusion 2018, 59: 169-176. PMID: 30520045, DOI: 10.1111/trf.15069.Peer-Reviewed Original ResearchConceptsPlatelet transfusion practicesImmune thrombocytopeniaPlatelet transfusionsNational Inpatient SampleAdmission diagnosisTransfusion practiceCurrent guidelinesHigher mean total hospital chargesMean total hospital chargesSmall bed size hospitalsMultivariable logistic regression analysisPayer inpatient databasePrimary admission diagnosisSurgery/procedureTotal hospital chargesMajor operative proceduresLogistic regression analysisNon-teaching hospitalsInvasive surgical proceduresHospital mortalityMultivariable adjustmentITP patientsClinical outcomesRelated hospitalizationsHospital chargesFrom trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea
Sinha C, Bakshi N, Ross D, Krishnamurti L. From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea. PLOS ONE 2018, 13: e0199375. PMID: 29949647, PMCID: PMC6021071, DOI: 10.1371/journal.pone.0199375.Peer-Reviewed Original ResearchConceptsSickle cell diseaseGroup 1 participantsGroup 2 participantsCell diseaseSide effectsAdult SCD patientsPatient-related factorsPotential side effectsAdult patientsSCD patientsHU usePatients' attitudesAge 31Age groupsAge 18PatientsYoung adultsEfficacySignificant differencesAdultsEffective alternativeDiseaseRiskParticipantsQualitative interviews
2015
Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use
Telen M, Wun T, McCavit T, De Castro L, Krishnamurti L, Lanzkron S, Hsu L, Smith W, Rhee S, Magnani J, Thackray H. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood 2015, 125: 2656-2664. PMID: 25733584, PMCID: PMC4408290, DOI: 10.1182/blood-2014-06-583351.Peer-Reviewed Original ResearchConceptsVaso-occlusive crisisSickle cell diseaseComposite primary end pointPrimary end pointPhase 2 studyEnd pointRandomized phase 2 studySCD vaso-occlusive crisisOpioid analgesic useSecondary end pointsActive treatment groupPhase 3 studyVaso-occlusive eventsAnalgesic usePlacebo groupProspective multicenterStudy drugAdverse eventsOpioid useSymptom reliefMedian timeSCD patientsCell diseaseTreatment groupsAnimal modelsPlatelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality
Goel R, Ness P, Takemoto C, Krishnamurti L, King K, Tobian A. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood 2015, 125: 1470-1476. PMID: 25588677, PMCID: PMC4342358, DOI: 10.1182/blood-2014-10-605493.Peer-Reviewed Original ResearchConceptsImmune thrombocytopenic purpuraThrombotic thrombocytopenic purpuraAcute myocardial infarctionPlatelet transfusionsArterial thrombosisVenous thrombosisHigher oddsHospital mortalityThrombocytopenic purpuraGender-adjusted odds ratioPlatelet transfusion practicesNationwide Inpatient SampleConsumptive disordersHIT patientsTransfusion practiceInpatient SampleMyocardial infarctionClinical severityOdds ratioTransfusionThrombosisPrimary mediatorMortalityLittle dataPurpura
2014
Prevalence of the βS Gene Among Scheduled Castes, Scheduled Tribes and Other Backward Class Groups in Central India
Shrikhande A, Arjunan A, Agarwal A, Dani A, Tijare J, Gettig E, Krishnamurti L. Prevalence of the βS Gene Among Scheduled Castes, Scheduled Tribes and Other Backward Class Groups in Central India. Hemoglobin 2014, 38: 230-235. PMID: 25023085, DOI: 10.3109/03630269.2014.931287.Peer-Reviewed Original ResearchConceptsSickle cell diseaseCommunity screeningCell diseaseVasoocclusive crisisComprehensive care programHigh-risk individualsSickle cell traitPneumococcal infectionDisease counselingWorld patientsUndiagnosed casesHigh prevalencePremature mortalityRisk individualsOrgan toxicityCare programEthnic groupsCell traitPrevalenceInherited disorderDistrict of NagpurDiseaseScheduled TribesPatientsScreeningRisk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom
Gladwin M, Barst R, Gibbs J, Hildesheim M, Sachdev V, Nouraie M, Hassell K, Little J, Schraufnagel D, Krishnamurti L, Novelli E, Girgis R, Morris C, Rosenzweig E, Badesch D, Lanzkron S, Castro O, Taylor J, Goldsmith J, Kato G, Gordeuk V, Machado R, Investigators and Patients O. Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom. PLOS ONE 2014, 9: e99489. PMID: 24988120, PMCID: PMC4079316, DOI: 10.1371/journal.pone.0099489.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnemia, Sickle CellBlood Flow VelocityBlood PressureCohort StudiesCreatinineFemaleFerritinsFollow-Up StudiesHemolysisHumansHypertension, PulmonaryKaplan-Meier EstimateMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsProportional Hazards ModelsRisk FactorsSeverity of Illness IndexUnited KingdomUnited StatesWalkingConceptsTricuspid regurgitation velocitySickle cell diseaseNT-proBNPCell diseaseMean pulmonary artery pressurePg/Pulmonary artery systolic pressurePulmonary artery pressureRisk of deathCause of mortalityPositive predictive valuePg/mLArtery pressurePulmonary hypertensionChronic transfusionScreening cohortHemolytic markersSystolic pressureCumulative survivalMale genderRisk factorsHigh riskPredictive valueClass IIIPatients
2013
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease
Wun T, Soulieres D, Frelinger A, Krishnamurti L, Novelli E, Kutlar A, Ataga K, Knupp C, McMahon L, Strouse J, Zhou C, Heath L, Nwachuku C, Jakubowski J, Riesmeyer J, Winters K. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. Journal Of Hematology & Oncology 2013, 6: 17. PMID: 23414938, PMCID: PMC3585853, DOI: 10.1186/1756-8722-6-17.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnemia, Sickle CellBiomarkers, TumorCell Adhesion MoleculesDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMicrofilament ProteinsMiddle AgedPainPhosphoproteinsPiperazinesPlatelet ActivationPlatelet Aggregation InhibitorsPrasugrel HydrochloridePrognosisPurinergic P2Y Receptor AntagonistsThiophenesYoung AdultConceptsSickle cell diseaseHemorrhagic eventsAdult patientsAntiplatelet agentsSCD patientsCell diseaseP-selectinMedical interventionsMulticenter phase 2 studyPlatelet surface P-selectinMethodsThe primary endpointPlatelet activation biomarkersSafety of prasugrelSerious hemorrhagic eventsPlacebo-controlled studyPhase 2 studyVivo platelet activationSoluble P-selectinSurface P-selectinThienopyridine antiplatelet agentPain ratePrasugrel armPrimary endpointActivation biomarkersStudy arms
2011
Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom
Sachdev V, Kato G, Gibbs J, Barst R, Machado R, Nouraie M, Hassell K, Little J, Schraufnagel D, Krishnamurti L, Novelli E, Girgis R, Morris C, Rosenzweig E, Badesch D, Lanzkron S, Castro O, Taylor J, Hannoush H, Goldsmith J, Gladwin M, Gordeuk V. Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom. Circulation 2011, 124: 1452-1460. PMID: 21900080, PMCID: PMC3183314, DOI: 10.1161/circulationaha.111.032920.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnemia, Sickle CellChildEchocardiographyExercise TestExercise ToleranceFamilial Primary Pulmonary HypertensionFemaleHomozygoteHumansHypertension, PulmonaryMaleMiddle AgedMultivariate AnalysisPredictive Value of TestsProspective StudiesPulmonary ArteryTricuspid Valve InsufficiencyUnited KingdomUnited StatesVentricular Dysfunction, LeftYoung AdultConceptsTricuspid regurgitation velocitySickle cell diseaseSickle cell anemiaVentricular diastolic dysfunctionDiastolic dysfunctionCell diseaseCell anemiaPulmonary hypertensionExercise capacityWalk distanceElevated pulmonary artery systolic pressurePulmonary artery systolic pressureSystolic pulmonary artery pressureHomozygous sickle cell anemiaPulmonary pressure elevationLV diastolic dysfunctionLV filling pressurePoor exercise capacityPulmonary artery pressureElevated pulmonary pressuresLong-term outcomesHomozygous hemoglobin SBlood urea nitrogenArtery pressureEchocardiographic markersHospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity
Machado R, Barst R, Yovetich N, Hassell K, Kato G, Gordeuk V, Gibbs J, Little J, Schraufnagel D, Krishnamurti L, Girgis R, Morris C, Rosenzweig E, Badesch D, Lanzkron S, Onyekwere O, Castro O, Sachdev V, Waclawiw M, Woolson R, Goldsmith J, Gladwin M. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 2011, 118: 855-864. PMID: 21527519, PMCID: PMC3148167, DOI: 10.1182/blood-2010-09-306167.Peer-Reviewed Original ResearchConceptsTricuspid regurgitation velocitySickle cell diseaseLower exercise capacityExercise capacityCell diseaseN-terminal pro-brain natriuretic peptideElevated tricuspid regurgitation velocityPro-brain natriuretic peptideSerious adverse eventsPulmonary arterial hypertensionSildenafil trialArterial hypertensionAdverse eventsWalk distanceDoppler echocardiographySCD patientsHospitalization ratesNatriuretic peptidePatientsSildenafilPredominant causePainHospitalizationTreatment effectsDisease
2009
Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)
Rao V, Price S, Perkins K, Aldridge P, Tretler J, Davis J, Dale J, Gill F, Hartman K, Stork L, Gnarra D, Krishnamurti L, Newburger P, Puck J, Fleisher T. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatric Blood & Cancer 2009, 52: 847-852. PMID: 19214977, PMCID: PMC2774763, DOI: 10.1002/pbc.21965.Peer-Reviewed Original ResearchConceptsAutoimmune lymphoproliferative syndromeAutoimmune hemolytic anemiaRefractory immune thrombocytopeniaMedian response durationUse of rituximabDisorder of apoptosisMarked lymphadenopathyProlonged neutropeniaRituximab infusionRituximab useSurgical splenectomyALPS patientsImmune thrombocytopeniaPalpable spleenRituximab therapySignificant splenomegalyPolysaccharide vaccineAutoimmune destructionMedication optionsMultilineage cytopeniasRefractory cytopeniaAutoreactive lymphocytesAsplenic individualsAntibody responseLymphoproliferative syndrome